Stepping down asthma treatment: How and when

Current Opinion in Pulmonary Medicine

Volumn 18, Issue 1, 2012, Pages 70-75

  Rogers, Linda ^a   Reibman, Joan ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

asthma; inhaled corticosteroids; long acting beta agonists; step down

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; LEUKOTRIENE RECEPTOR AFFECTING AGENT; OMALIZUMAB; PLACEBO;

ASTHMA; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRACTICE GUIDELINE; REVIEW;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS;

EID: 83155180230     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32834db017     Document Type: Review

References (55)

1. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007; 120 (5 Suppl):S94-S138.
2. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31:143-178.
3. Peters SP. Safety of inhaled corticosteroids in the treatment of persistent asthma. J Natl Med Assoc 2006; 98:851-861. (Pubitemid 43846242)
4. O'Byrne PM, Pedersen S, Carlsson LG, et al. Risks of pneumonia in patients with asthma taking inhaled corticosteroids. Am J Respir Crit Care Med 2011; 183:589-595.
5. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-789. (Pubitemid 46294610)
6. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123:1001-1006.
7. Dupont C, Giraud V, Leporrier J, et al. Cushing's syndrome induced by combined treatment with inhaled fluticasone and oral ritonavir. Rev Mal Respir 2009; 26:779-782.
8. Gulliver T, Morton R, Eid N. Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. Paediatr Drugs 2007; 9:185-194. (Pubitemid 46849138)
9. Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377:650-657.
10. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26. (Pubitemid 43265239)
11. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 2000; 343:1054-1063.
12. Raissy HH, Sternberg AL, Williams P, et al. Risk of cataracts in the Childhood Asthma Management Program Cohort. J Allergy Clin Immunol 2010; 126:389-392, 392 e1-392 e4.
13. Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest 2006; 130 (1 Suppl):65S-72S. (Pubitemid 44107237)
14. Irwin RS, Richardson ND. Side effects with inhaled corticosteroids: the physician's perception. Chest 2006; 130 (1 Suppl):41S-53S. (Pubitemid 44107235)
15. Juniper EF, Kline PA, Vanzieleghem MA, Hargreave FE. Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. J Allergy Clin Immunol 1991; 87:483-489.
16. Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331:700-705. (Pubitemid 24275742)
17. Hawkins G, McMahon AD, Twaddle S, et al. Stepping down inhaled corticosteroids in asthma: randomised controlled trial. BMJ 2003; 326: 1115.
18. Lemanske RF Jr, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001; 285:2594-2603. (Pubitemid 32479899)
19. Waalkens HJ, Van Essen-Zandvliet EE, Hughes MD, et al. Cessation of longterm treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration. The Dutch CNSLD Study Group. Am Rev Respir Dis 1993; 148:1252-1257. (Pubitemid 23326022)
20. Kwong KY, Morphew T, Scott L, et al. Asthma control and future asthmarelated morbidity in inner-city asthmatic children. Ann Allergy Asthma Immunol 2008; 101:144-152.
21. Tsurikisawa N, Tsuburai T, Oshikata C, et al. Prognosis of adult asthma after normalization of bronchial hyperresponsiveness by inhaled corticosteroid therapy. J Asthma 2008; 45:445-451. (Pubitemid 351961491)
22. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-1721. (Pubitemid 35447900)
23. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27:483-494. (Pubitemid 43372521)
24. Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352:2163-2173.
25. Shaw DE, Berry MA, Thomas M, et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 2007; 176:231-237. (Pubitemid 47195872)
26. Leuppi JD, Salome CM, Jenkins CR, et al. Markers of airway inflammation and airway hyperresponsiveness in patients with well controlled asthma. Eur Respir J 2001; 18:444-450. (Pubitemid 32895628)
27. Koenig SM, Murray JJ, Wolfe J, et al. Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma? Respir Med 2008; 102:665-673.
28. Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and metaanalysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2010 [Epub ahead of print].
29. Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 2007; 356:2040-2052. (Pubitemid 46789894)
30. Stempel DA, Stoloff SW, Carranza Rosenzweig JR, et al. Adherence to asthma controller medication regimens. Respir Med 2005; 99:1263-1267. (Pubitemid 41245312)
31. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of longacting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010:CD005535.
32. Ducharme FM, Lasserson TJ, Cates CJ. Addition to inhaled corticosteroids of long-acting beta2-agonists versus antileukotrienes for chronic asthma. Cochrane Database Syst Rev 2011:CD003137.
33. Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362:975-985.
34. Deykin A, Wechsler ME, Boushey HA, et al. Combination therapy with a longacting beta-agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med 2007; 175:228-234. (Pubitemid 46203125)
35. Peters SP, Anthonisen N, Castro M, et al. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 2007; 356:2027-2039. (Pubitemid 46789893)
36. Koenig SM, Ostrom N, Pearlman D, et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are 'stepped-down'. J Asthma 2008; 45:681-687.
37. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139:28-35.
38. Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364:1005-1015.
39. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006; 354:2689-2695.
40. FDA Drug Safety Communication. New safety controls for long-acting inhaled asthma medications called long-acting beta-agonists (LABAs). Safety Announcement [02-18-2010]. United States Food and Drug Administration (FDA); 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnounce ments/ucm200931.htm [accessed 13 April, 2010].
41. European Medicines Agency. Long-acting beta2-adrenoceptor agonist bronchodilators formoterol and salmeterol-review of safety in the management of asthma. Summary Assessment Report of the Pharmacovigilance Working Party. European Medicines Agency; 2010. www.ema.europa.eu/docs/en-GB/document-library/ Report/2010/10/WC500098462.pdf [accessed 27 July, 2011].
42. Fowler SJ, Currie GP, Lipworth BJ. Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone. J Allergy Clin Immunol 2002; 109:929-935. (Pubitemid 34634301)
43. Bateman ED, Jacques L, Goldfrad C, et al. Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. J Allergy Clin Immunol 2006; 117:563-570. (Pubitemid 43340219)
44. Godard P, Greillier P, Pigearias B, et al. Maintaining asthma control in persistent asthma: comparison of three strategies in a 6-month double-blind randomised study. Respir Med 2008; 102:1124-1131.
45. Reddel HK, Gibson PG, Peters MJ, et al. Down-titration from high-dose combination therapy in asthma: removal of long-acting beta(2)-agonist. Respir Med 2010; 104:1110-1120.
46. Hagiwara M, Delea TE, Stanford RH, Stempel DA. Stepping down to fluticasone propionate or a lower dose of fluticasone propionate/salmeterol combination in asthma patients recently initiating combination therapy. Allergy Asthma Proc 2010; 31:203-210.
47. FDA Drug Safety Communication. FDA requires postmarket safety trials for long-acting beta-agonists (LABAs). United States Food and Drug Administration (FDA); 2011. www.fda.gov/Drugs/DrugSafety/ucm251512. htm [accessed 27 July, 2011].
48. Cates CJ, Lasserson TJ. Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev 2009:CD007313.
49. Berger WE, Bleecker ER, O'Dowd L, et al. Efficacy and safety of budesonide/formoterol pressurized metered-dose inhaler: randomized controlled trial comparing once-and twice-daily dosing in patients with asthma. Allergy Asthma Proc 2010; 31:49-59.
50. Cates CJ, Lasserson TJ. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2010:CD007694.
51. Powell H, Gibson PG. Initial starting dose of inhaled corticosteroids in adults with asthma: a systematic review. Thorax 2004; 59:1041-1045. (Pubitemid 39573922)
52. Zhang L, Axelsson I, Chung M, Lau J. Dose response of inhaled corticosteroids in children with persistent asthma: a systematic review. Pediatrics 2011; 127:129-138.
53. FitzGerald JM, Boulet LP, Follows RM. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther 2005; 27:393-406. (Pubitemid 40732647)
54. Kelly HW. Inhaled corticosteroid dosing: double for nothing? J Allergy Clin Immunol 2011; 128:278-281.e2.
55. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003; 361:1071-1076. (Pubitemid 36369558)